ADMA Biologics gets grant for treatment of upper respiratory tract infection with immunotherapeutic composition

ADMA Biologics Inc's innovative method for treating upper respiratory infections caused by S. pneumonia with hyperimmune globulin composition.

Related Posts

America’s ERs struggle with timely care for stroke pati...

Aug 15, 2023

ProMED, an early warning system on disease outbreaks, a...

Aug 3, 2023

Islet transplantation for type 1 diabetes: Do regulator...

Oct 9, 2023